An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab

Abstract

Based on these observations, the low-dose rheumatoid arthritis protocol should not be recommended due to the inferior clinical response and shortened time to relapse.

Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey

“…In another review, groups treated according to each protocol were found to show similar rates of serious adverse events and mortality . A review conducted by Amber and Hertl found no significant difference in the percentage of patients achieving complete remission between those treated according to the lymphoma versus the RA treatment protocol . However, the lymphoma treatment protocol was identified as superior in terms of risk for relapse in this review .…”

Mucosal involvement is a risk factor for poor clinical outcomes and relapse in patients with pemphigus treated with rituximab

“…Before its application to pemphigus, rituximab had been approved for non-Hodgkin's lymphoma and rheumatoid arthritis, and both have different protocols. Both the lymphoma and rheumatoid arthritis protocols have been applied to the treatment of pemphigus (Ahmed & Shetty, 2015;Amber & Hertl, 2015;Cho et al, 2014;Kanwar et al, 2014;Kim, Kim, Kim, & Kim, 2011;Wang et al, 2015).…”

Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

“…38 Lower doses of rituximab are less effective 39,40 • Rituximab can be combined with short-term (<4 months old) systemic corticosteroids and long-term (>12 months old) immunosuppressive treatment…”